Alexander Ney
YOU?
Author Swipe
View article: Endoscopic, ultrasound-guided, radiofrequency ablation of aldosterone-producing adenomas (FABULAS): a UK, multicentre, prospective, proof-of-concept trial
Endoscopic, ultrasound-guided, radiofrequency ablation of aldosterone-producing adenomas (FABULAS): a UK, multicentre, prospective, proof-of-concept trial Open
National Institute for Health and Care Research Biomedical Research Centres at Barts, University College Hospitals, and Cambridge University Hospitals, Barts Charity, and British Heart Foundation.
View article: Identification of a serum proteomic biomarker panel using diagnosis specific ensemble learning and symptoms for early pancreatic cancer detection
Identification of a serum proteomic biomarker panel using diagnosis specific ensemble learning and symptoms for early pancreatic cancer detection Open
Background The grim (<10% 5-year) survival rates for pancreatic ductal adenocarcinoma (PDAC) are attributed to its complex intrinsic biology and most often late-stage detection. The overlap of symptoms with benign gastrointestinal conditio…
View article: Endoscopic, ultrasound guided, radiofrequency ablation of aldosterone producing adenomas: A prospective, proof-of-concept trial
Endoscopic, ultrasound guided, radiofrequency ablation of aldosterone producing adenomas: A prospective, proof-of-concept trial Open
Unilateral aldosterone-producing adrenal adenomas (APAs) are the potentially curable cause of 5% of all cases of hypertension. At present surgical removal of a whole gland is the only approved option for achieving cure, with uncertain long…
View article: Identification of a serum proteomic biomarker panel using diagnosis specific ensemble learning and symptoms for early pancreatic cancer detection
Identification of a serum proteomic biomarker panel using diagnosis specific ensemble learning and symptoms for early pancreatic cancer detection Open
BACKGROUND The grim (<10% 5-year) survival rates for pancreatic ductal adenocarcinoma (PDAC) are attributed to its complex intrinsic biology and most often late-stage detection. The overlap of symptoms with benign gastrointestinal conditio…
View article: THU594 Outcome Data From Fabulas: A Feasibility Study Of Radiofrequency Endoscopic Ablation, With Ultrasound Guidance, As A Non-surgical, Adrenal Sparing Treatment For Aldosterone Producing Adenomas
THU594 Outcome Data From Fabulas: A Feasibility Study Of Radiofrequency Endoscopic Ablation, With Ultrasound Guidance, As A Non-surgical, Adrenal Sparing Treatment For Aldosterone Producing Adenomas Open
Disclosure: G. Argentesi: None. X. Wu: None. A. Ney: None. E. Goodchild: None. K. Laycock: None. Y. Lee: None. R. Senanayake: None. J. MacFarlane: None. E. Ng: None. J. Kearney: None. A. Palma: None. I. Munteanu: None. J. Salsbury: None. E…
View article: Performance and Safety of EUS Ablation Techniques for Pancreatic Cystic Lesions: A Systematic Review and Meta-Analysis
Performance and Safety of EUS Ablation Techniques for Pancreatic Cystic Lesions: A Systematic Review and Meta-Analysis Open
Background: Pancreatic cystic lesions (PCL) represent an increasingly diagnosed condition with significant burden to patients’ lives and medical resources. Endoscopic ultrasound (EUS) ablation techniques have been utilized to treat focal p…
View article: Tissue-Specific Human Extracellular Matrix Scaffolds Promote Pancreatic Tumour Progression and Chemotherapy Resistance
Tissue-Specific Human Extracellular Matrix Scaffolds Promote Pancreatic Tumour Progression and Chemotherapy Resistance Open
Over 80% of patients with pancreatic ductal adenocarcinoma (PDAC) are diagnosed at a late stage and are locally advanced or with concurrent metastases. The aggressive phenotype and relative chemo- and radiotherapeutic resistance of PDAC is…
View article: Early detection of pancreatic ductal adenocarcinomas with an ensemble learning model based on a panel of protein serum biomarkers
Early detection of pancreatic ductal adenocarcinomas with an ensemble learning model based on a panel of protein serum biomarkers Open
Earlier detection of pancreatic ductal adenocarcinoma (PDAC) is key to improving patient outcomes, as it is mostly detected at advanced stages which are associated with poor survival. Developing non-invasive blood tests for early detection…
View article: Biliary Strictures and Cholangiocarcinoma – Untangling a Diagnostic Conundrum
Biliary Strictures and Cholangiocarcinoma – Untangling a Diagnostic Conundrum Open
Cholangiocarcinoma is an uncommon and highly aggressive biliary tract malignancy with few manifestations until late disease stages. Diagnosis is currently achieved through a combination of clinical, biochemical, radiological and histologic…
View article: The State-of-the-Art of Phase II/III Clinical Trials for Targeted Pancreatic Cancer Therapies
The State-of-the-Art of Phase II/III Clinical Trials for Targeted Pancreatic Cancer Therapies Open
Pancreatic cancer is a devastating disease with very poor prognosis. Currently, surgery followed by adjuvant chemotherapy represents the only curative option which, unfortunately, is only available for a small group of patients. The majori…
View article: A combination of urinary biomarker panel and PancRISK score for earlier detection of pancreatic cancer: A case–control study
A combination of urinary biomarker panel and PancRISK score for earlier detection of pancreatic cancer: A case–control study Open
Background Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with around 9% of patients surviving >5 years. Asymptomatic in its initial stages, PDAC is mostly diagnosed late, when already a locally advanced or metast…
View article: Modelling Pancreatic Neuroendocrine Cancer: From Bench Side to Clinic
Modelling Pancreatic Neuroendocrine Cancer: From Bench Side to Clinic Open
Pancreatic neuroendocrine tumours (pNETs) are a heterogeneous group of epithelial tumours with neuroendocrine differentiation. Although rare (incidence of <1 in 100,000), they are the second most common group of pancreatic neoplasms after …
View article: SAT-546 Endoscopic Ultrasound-Guided Radiofrequency Ablation (EUS-RFA) as an Alternative to Adrenalectomy for the Treatment of Aldosterone-Producing Adenomas (APAs)
SAT-546 Endoscopic Ultrasound-Guided Radiofrequency Ablation (EUS-RFA) as an Alternative to Adrenalectomy for the Treatment of Aldosterone-Producing Adenomas (APAs) Open
Primary Aldosteronism (PA) carries significant cardiometabolic risk, over and above those attributable to hypertension alone. The Endocrine Society guidelines recommend adrenalectomy in those with unilateral disease. However surgery is lik…